Axsome Therapeutics Inc. (AXSM)
NASDAQ: AXSM
· Real-Time Price · USD
116.76
0.75 (0.65%)
At close: Sep 26, 2025, 3:59 PM
115.00
-1.51%
After-hours: Sep 26, 2025, 07:48 PM EDT
Axsome Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | 148.96M | 120.36M | 203.84M | 103.74M | 86.52M | 74.1M | 70.75M | 57.13M | 46.02M | 28.57M |
| Product Revenue Growth | +23.76% | -40.96% | +96.50% | +19.90% | +16.77% | +4.73% | +23.84% | +24.14% | +61.07% | n/a |
| Royalty Revenue | 1.08M | 1.1M | n/a | 1.03M | 646K | 903K | 783K | 667K | 683K | 272K |
| Royalty Revenue Growth | -1.99% | n/a | n/a | +58.82% | -28.46% | +15.33% | +17.39% | -2.34% | +151.10% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 2.51M | 1.1M | 1.01M | 1.03M | 1.08M | 903K | 1.35M |
| Non-Us Revenue Growth | +127.42% | +9.30% | -1.46% | -4.65% | +19.16% | -32.91% | n/a |
| United States Revenue | 146.45M | 119.41M | 116.63M | 102.81M | 85.44M | 73.27M | 55.78M |
| United States Revenue Growth | +22.64% | +2.38% | +13.45% | +20.32% | +16.61% | +31.35% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 130.28M | 120.79M | 113.27M | 95.56M | 103.55M | 98.97M | 86.81M | 83.19M | 78.94M | 74.19M | 61.5M | 40.89M | 31.16M | 25.7M | 18.83M | 20.23M | 16.34M | 11.25M | 10.36M | 6.33M | 7.24M | 4.97M | 5.22M | 3.11M | 2.45M | 2.82M | 2.3M | 2.2M | 2.44M | 2.41M | 1.95M | 1.83M | 1.74M | 1.69M | 1.82M | 1.64M | 1.53M | 1.36M | 946.62K | 499.42K | 456.41K | 516.84K |
| Selling, General, and Administrative Revenue Growth | +7.86% | +6.64% | +18.53% | -7.72% | +4.63% | +14.01% | +4.35% | +5.39% | +6.39% | +20.64% | +50.39% | +31.23% | +21.23% | +36.53% | -6.92% | +23.75% | +45.30% | +8.58% | +63.62% | -12.50% | +45.59% | -4.84% | +67.85% | +27.26% | -13.25% | +22.59% | +4.38% | -9.69% | +1.18% | +23.61% | +6.79% | +4.76% | +3.35% | -7.26% | +10.97% | +7.18% | +12.72% | +43.31% | +89.54% | +9.42% | -11.69% | n/a |
| Research and Development Revenue | 49.54M | 44.78M | 55.25M | 45.39M | 49.85M | 36.59M | 30.8M | 28.77M | 20.58M | 17.79M | 14.69M | 14.88M | 15.79M | 12.59M | 13.78M | 13.18M | 14.5M | 16.6M | 17.38M | 14.8M | 10.54M | 27.52M | 19.21M | 15.84M | 11M | 7.6M | 7.15M | 6.04M | 5.55M | 4.75M | 4.49M | 4.47M | 5.01M | 5.99M | 5.81M | 5.57M | 5.3M | 4.53M | 2.21M | 1.52M | 1.63M | 1.42M |
| Research and Development Revenue Growth | +10.62% | -18.94% | +21.72% | -8.96% | +36.26% | +18.78% | +7.08% | +39.77% | +15.67% | +21.10% | -1.24% | -5.80% | +25.48% | -8.68% | +4.56% | -9.12% | -12.61% | -4.54% | +17.50% | +40.34% | -61.69% | +43.30% | +21.28% | +43.92% | +44.72% | +6.32% | +18.38% | +8.83% | +16.79% | +5.75% | +0.51% | -10.71% | -16.34% | +3.07% | +4.27% | +5.11% | +17.05% | +105.00% | +44.84% | -6.39% | +14.98% | n/a |